Sera Prognostics, Inc. (NASDAQ:SERA) Director Sells $77,721.57 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,163 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the completion of the transaction, the director now directly owns 2 shares in the company, valued at $12.78. This trade represents a 99.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Joshua Phillips also recently made the following trade(s):

• On Friday, January 10th, Joshua Phillips sold 12,710 shares of Sera Prognostics stock. The stock was sold at an average price of $7.40, for a total transaction of $94,054.00.

Sera Prognostics Stock Down 0.2 %

Shares of Sera Prognostics stock opened at $6.60 on Friday. Sera Prognostics, Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $12.35. The company has a fifty day moving average of $7.40 and a 200 day moving average of $7.31.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the previous year, the business posted ($0.23) EPS. On average, analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its position in shares of Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after buying an additional 75,441 shares during the last quarter. Rhumbline Advisers purchased a new stake in Sera Prognostics during the 2nd quarter valued at about $190,000. American Century Companies Inc. boosted its position in Sera Prognostics by 12.7% in the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after buying an additional 2,891 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Sera Prognostics during the second quarter worth $162,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Sera Prognostics in the 2nd quarter valued at about $68,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.